Lixte Biotechnology (LIXT) News Today → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Free LIXT Stock Alerts $2.40 +0.02 (+0.84%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14, 2024 | americanbankingnews.comContrasting Evotec (OTCMKTS:EVTCY) & Lixte Biotechnology (NASDAQ:LIXT)May 8, 2024 | globenewswire.comLIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”April 24, 2024 | theglobeandmail.comMixed Shelf Filing Gives Micro Cap Delayed BoostMarch 29, 2024 | stockhouse.comNEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE'S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIESMarch 27, 2024 | theglobeandmail.comBiotech Steals The Show Following Pre-Clinical Data AnnouncementMarch 27, 2024 | msn.comLixte stock soars on preclinical data for lead drug LB-100March 27, 2024 | marketwatch.comLixte Biotechnology Shares Rise 51% After Positive Data for LB-100 Cancer TreatmentMarch 21, 2024 | globenewswire.comLIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer TreatmentsFebruary 27, 2024 | globenewswire.comProfessor René Bernards to Present New Pre-Clinical Data on LIXTE's LB-100 at Joint Conference of European and American Associations for Cancer ResearchFebruary 26, 2024 | globenewswire.comLIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCINovember 14, 2023 | finanznachrichten.deLixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Provides Update on Clinical Progress and Expanding CollaborationsNovember 13, 2023 | finance.yahoo.comLIXTE Biotechnology Provides Update on Clinical Progress and Expanding CollaborationsNovember 9, 2023 | morningstar.comLixte Biotechnology Holdings Inc LIXTOctober 16, 2023 | finance.yahoo.comLIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand CollaborationSeptember 26, 2023 | finance.yahoo.comLIXTE Appoints Bas van der Baan as President and Chief Executive OfficerAugust 27, 2023 | wsj.comLixte Biotechnology Holdings Inc. WtJuly 20, 2023 | finance.yahoo.comLIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq RulesJuly 18, 2023 | benzinga.comWhy Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionJuly 18, 2023 | msn.comLIXTE Biotechnology falls after company launches $3.5M registered direct offering of sharesJuly 18, 2023 | marketwatch.comLixte Bio Shares Tumble 31% After Pricing $3.5M Stock OfferingJuly 18, 2023 | finance.yahoo.comLIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq RulesJuly 17, 2023 | marketwatch.comLixte Biotechnology Shares Rise 25% on LB-100 Cancer Treatment ResearchJuly 17, 2023 | msn.comWhat's Going On With Lixte Biotechnology (LIXT) Stock?July 17, 2023 | marketbeat.comTrading was temporarily halted for "LIXT" at 10:07 AM with a stated reason of "LULD pause."July 17, 2023 | marketbeat.comTrading was temporarily halted for "LIXT" at 10:07 AM with a stated reason of "LULD pause."July 17, 2023 | marketbeat.comTrading was temporarily halted for "LIXT" at 10:07 AM with a stated reason of "LULD pause."July 17, 2023 | marketbeat.comTrading was temporarily halted for "LIXT" at 09:07 AM with a stated reason of "LULD pause."July 17, 2023 | finance.yahoo.comPreclinical Results of LIXTE Biotechnology’s Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE’s Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and ChemotherapyJune 23, 2023 | finance.yahoo.comLIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing RequirementsJune 7, 2023 | finance.yahoo.comLIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b/2 Randomized Trial of Doxorubicin +/- LIXTE’s Lead Anti-Cancer Compound, LB-100, in Advanced Soft Tissue SarcomasJune 5, 2023 | finance.yahoo.comOwning 53% in Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) means that insiders are heavily invested in the company's futureJune 2, 2023 | msn.comLIXTE Biotechnology Holdings announces reverse stock split to obtain minimum price complianceJune 2, 2023 | marketwatch.comLixte Biotech Shares Down 8% After Company Announces Reverse Stock SplitJune 2, 2023 | finance.yahoo.comLIXTE Biotechnology Holdings, Inc. Announces 1-for-10 Reverse Stock Split of its Common Stock Effective on Pre-Market Opening on June 5, 2023May 30, 2023 | finance.yahoo.comRecently Published Independent Research Reveals New Mechanisms by Which LIXTE Biotechnology’s Lead Clinical Compound, LB-100, Increases Effectiveness of Cancer ImmunotherapyMay 12, 2023 | marketwatch.com8-K: LIXTE BIOTECHNOLOGY HOLDINGS, INC.April 28, 2023 | marketwatch.comGlobal Neurometabolic Disorders Market Share 2023-2030 with On-going Demand StatusApril 24, 2023 | finance.yahoo.comLIXTE Biotechnology Reports First Spanish Site Activated to Begin Accrual of Patients for a Phase 1b/2 Clinical Trial of LIXTE's Lead Anti-Cancer Compound, LB-100, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue SarcomaApril 4, 2023 | finance.yahoo.comLIXTE Biotechnology Announces Sarah Cannon Research Institute Joins City of Hope’s Ongoing Phase 1b Clinical Trial in Evaluating Lixte’s Lead Anti-Cancer Compound, LB-100, in Small Cell Lung CancerMarch 24, 2023 | marketwatch.comGaucher Disease Drugs Market Top Players By 2031March 21, 2023 | marketwatch.comProtein Phosphatase 2A Market Top Players and Forecast till 2028February 21, 2023 | marketwatch.comGaucher Disease Drugs Market Massive Growth Strikes Due To Technological Innovation During 2023-2028February 14, 2023 | finance.yahoo.comLIXTE BIOTECHNOLOGY HOLDINGS REPORTS NEWLY PUBLISHED INDEPENDENT PRE-CLINICAL RESEARCHFebruary 13, 2023 | finance.yahoo.comLixte Biotechnology Holdings, Inc. (LIXTW)February 8, 2023 | finance.yahoo.comIs Lixte Biotechnology Holdings (NASDAQ:LIXT) In A Good Position To Invest In Growth?February 7, 2023 | finance.yahoo.comLIXTE Biotechnology Stock Jumps As Lead Program Shows Cancer Killing Activity In Animal ModelsFebruary 7, 2023 | finance.yahoo.comLIXTE BIOTECHNOLOGY HOLDINGS, INC. REPORTS THAT ITS LEAD CLINICAL COMPOUND, LB-100, CAN KILL CANCER CELLS THROUGH HYPER-STIMULATION OF CELL PROLIFERATION SIGNALS IN PRE-CLINICAL MODELSFebruary 7, 2023 | marketbeat.comTrading was temporarily halted for "LIXT" at 12:02 PM with a stated reason of "LULD pause."February 7, 2023 | marketbeat.comTrading was temporarily halted for "LIXT" at 12:02 PM with a stated reason of "LULD pause."January 26, 2023 | marketwatch.comGlobal Neurometabolic Disorders Market Size Growth Rate Analysis 2023 by Market Overview, Segments, Regions, Market Share and Forecast to 2028 Get Lixte Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for LIXT and its competitors with MarketBeat's FREE daily newsletter. Email Address The Overlooked Retirement Asset You Probably Don’t Own (Ad)4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm. Click here to access the Crypto Retirement Blueprint now. LIXT Media Mentions By Week LIXT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LIXT News Sentiment▼0.990.50▲Average Medical News Sentiment LIXT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LIXT Articles This Week▼10▲LIXT Articles Average Week Get Lixte Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for LIXT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ADIL News ENVB News HILS News OGEN News KTRA News KA News XBIO News AIMD News HOTH News ASLN News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LIXT) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersObama’s Forever Term [exposed]Porter & CompanyThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMost important medical advance in 100 yearsThe Oxford ClubThe Presidential candidate you should REALLY be worried aboutStansberry ResearchForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsClaim Your Complimentary Bitcoin RewardCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lixte Biotechnology Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
